Caption:
This high-resolution Cellvizio in vivo image shows the microvas- culature of pancreatic ductal adenocarcinoma as characterized by the tumor surface capillary. The technology may help detect disease earlier and understand tumor-host interaction at various stages of progression.

Click here for the unique, real time Cellvizio video.

Courtesy of Ken Lin and Umar Mahmood, Massachusetts General Hospital, Boston, MA

Company has been recognized as runner-up in the Medical Device category for breaking ground and demonstrating measurable impact on the field. See the Wall Street Journal's web site for more details.

Cellvizio was recently installed at two world renowned medical institutions. The University of Michigan Health System in Ann Arbor is utilizing Cellvizio for gastrointestinal and lung applications. The University's Center for Optical Molecular Imaging develops novel optical methods for early detection of cancer in the gastrointestinal tract.

The Karolinska Institute in Stockholm, one of Europe's largest medical universities, will begin using Cellvizio in October for the exploration of the biliary system.

The Institution's Department of Advanced Interventional Endoscopy performs 700 ERCP procedures each year, and department head Pr. Matthias Löhr, said "We believe Cellvizio is a very promising technique for the detection and characterization of cholangiocarcinoma and IPMN."

We recognize the importance of reimbursement to both physicians and hospitals and recently developed a reimbursement strategy that reflects the added value of Cellvizio for patients, providers and payers. We look forward to implementing this with our current and future Cellvizio users.

Please contact your local Cellvizio Market Development Manager
or Brian Tinkham, VP of Marketing (brian@maunakeatech.com) for more information.

David Wilson Medical Director at the Lung Center, Columbus Regional Hospital, Columbus, Indiana

Q: How long have you been using Cellvizio?
A: We initiated use of the Cellvizio System at the Lung Center earlier this year. We were impressed by all of the new clinical data on its use in a variety of indications and had followed the evolution of the confocal microscopy field for several years.

Q: How has Cellvizio helped you enhance your diagnosis of lung diseases?
A: Cellvizio provides an amazing amount of novel information. It increases diagnostic yield for peripheral nodules by real-time localization and pattern recognition, allows us to drive false-negatives much lower as benign granulomas are very recognizable with these images, and builds vast amounts of information about interstitial lung disease. Also, lung cancer detection rates are far higher in our anecdotal experience.

Q: What have been your experiences using Cellvizio on pulmonology patients to date?
A: We have a very large population here in terms of risk and morbidity. We have seen success in 35 cases to date and believe that over time that we'll eventually be able to avoid unnecessary biopsies. We are working with the company on a reimbursement strategy and expect a positive outcome. Ultimately, we believe Cellvizio will allow us to characterize small nodules in a way that we've never dreamed of before.